American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 733-736 , May 2009

Thrombocytosis in EPO-Treated Dialysis Patients May Be Mediated by EPO Rather Than Iron Deficiency

  • Nosratola D. Vaziri, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nosratola D. Vaziri, MD, University of California, Irvine, Division of Nephrology and Hypertension, 101 The City Dr, Bldg 53, Rm 125, Rt 81, Orange, CA 92868

References 

  1. Streja E, Kovesdy CP, Greenland S. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–736
  2. Kadikoylu G, Yavasoglu I, Bolaman Z, Senturk T. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc. 2006;98:398–402
  3. Besarab A, Bolton WK, Browne JK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  4. Singh AK, Szczech L, Tang KL. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  5. Drueke TB, Locatelli F, Clyne N. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  6. Littlewood TJ. Normalization of hemoglobin in patients with CKD may cause harm: But what is the mechanism?. Am J Kidney Dis. 2008;52:642–644
  7. Vaziri ND. Oxidative stress in chronic renal failure: The nature, mechanism and consequences. Semin Nephrol. 2004;24:469–473
  8. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538
  9. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol. 1993;3:1672–1679
  10. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983–2989
  11. Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest. 1987;79:286–289
  12. Dessypris EN, Gleaton JH, Armstrong OL. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol. 1987;65:265–269
  13. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85:1719–1726
  14. Sakaguchi M, Kawakita M, Matsushita J, Shibuya K, Koishihara Y, Takatsuki K. Human erythropoietin stimulates murine megakaryopoiesis in serum-free culture. Exp Hematol. 1987;15:1028–1034
  15. An E, Ogata K, Kuriya S, Nomura T. Interleuhn 6 and erythropoietin act as direct potentiators and inducers of in vitro cytoplasmic process formation on purified mouse megakaryocytes. Exp Hematol. 1994;22:149–156
  16. Segal GM, Stueve T, Adamson JW. Analysis of murine megakaryocyte colony size and ploidy: Effects of interleukin-3. J Cell Physiol. 1988;137:537–544
  17. Debili N, Masse J, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Effects of recombinant human hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor and leukemia inhibitor factor on megakaryocytic differentiation of CD34+ cells. Blood. 1993;82:84–95
  18. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568–571
  19. Porteu F, Rouyez MC, Cocault L, et al. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: Evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin. Mol Cell Biol. 1996;16:2473–2482
  20. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood. 1996;88:803–808
  21. Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int. 1992;42:668–672
  22. Tang WW, Stead RA, Goodkin DA. Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol. 1998;18:263–273
  23. Zhou XJ, Vaziri ND. Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant. 2002;17:992–997
  24. Kahraman S, Yilmaz R, Kirkpantur A, et al. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology. 2005;10:264–269
  25. Nagai T, Akizawa T, Kohjiro S, et al. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int. 1996;50:102–107
  26. Borawski J, Naumnik B, Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: Associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost. 2002;8:359–367
  27. Vaziri ND. Anemia and anemia correction: Surrogate markers or causes of mortality in chronic kidney disease. Nat Clin Pract Nephrol. 2008;4:436–445
  28. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821–828
  29. Vaziri ND, Zhou XJ: Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant (in press)
  30. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood. 2001;98:2720–2725

 Originally published online as doi:10.1053/j.ajkd.2008.12.030 on March 23, 2009.

PII: S0272-6386(09)00147-4

doi: 10.1053/j.ajkd.2008.12.030

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 733-736 , May 2009

Article Tools

* Image Usage & Resolution